We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
Sign in
Sign in
Companies → Spyre Therapeutics, Inc.
Save to list
Remove

Spyre Therapeutics, Inc.

United States, Waltham
Report a bug?
Claim ownership and edit
Description
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Industries
SIC
Address:

221 Crescent Street

Website:
Recent news:

VR Adviser Boosts Spyre Therapeutics Stake to $120.74 Million

VR Adviser increased its stake in preclinical biotech firm Spyre Therapeutics, with holdings now valued at $120.74 million, highlighting significant investment in IBD treatments.

Source: IndexBox Mar 19, 2026

VR Adviser Sells $71M in Ocular Therapeutix Shares in Q4 2025

Analysis of VR Adviser LLC's Q4 2025 sale of a $71 million stake in Ocular Therapeutix, detailing the transaction's impact on the fund's portfolio composition.

Source: IndexBox Mar 18, 2026

VR Adviser LLC Boosts Stake in Savara Inc. to $82.9 Million

VR Adviser LLC significantly increased its investment in clinical-stage biopharma Savara Inc. during the fourth quarter of 2025, as disclosed in a recent SEC filing.

Source: IndexBox Mar 15, 2026

Spyre Therapeutics Reports Q3 2025 Loss, Beats Expectations

Spyre Therapeutics announced a smaller-than-expected Q3 2025 loss of $0.15 per share, beating analyst forecasts of a $0.68 per share loss.

Source: IndexBox Nov 4, 2025

Spyre Therapeutics Reports Smaller-Than-Expected Q2 Loss

Spyre Therapeutics reports a better-than-expected Q2 loss, reflecting resilience in the growing biotechnology sector.

Source: IndexBox Aug 5, 2025

IBM Unveils New Power-Efficient Data Center Chips and Servers

Explore IBM's Power11 chips and servers, offering power efficiency and AI integration, enhancing security and reliability for specialized sectors.

Source: IndexBox Jul 8, 2025

XNAS - Delayed Quote - USD
SYRE
41.25 -1.06 (-2.51%)
At close March 23 07:15 UTC
Candle
Line
1D
5D
1M
6M
1Y
5Y
Financial Statistics
Valuation Measures
Current
Quarterly
As of 06/22/2025
Market Cap: 904.70 M
Enterprise Value: 750.35 M
Trailing P/E: N/A
Forward P/E: -3.63
PEG Ratio (5yr expected): N/A
Price/Sales (ttm): N/A
Price/Book (mrq): 2.77
Enterprise Value/Revenue: N/A
Enterprise Value/EBITDA: N/A
Financial Highlights
Profitability and Income Statement
Profit Margin: N/A%
Return on Assets (ttm): -25.34%
Return on Equity (ttm): -65.82%
Revenue (ttm): N/A
Net Income Avi to Common (ttm): -159.24 M
Diluted EPS (ttm): -3.06
Balance Sheet and Cash Flow
Total Cash (mrq): 564.82 M
Total Debt/Equity (mrq): N/A%
Levered Free Cash Flow (ttm): -68.57 M
Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.